Table 1 Study subjects (mean ± SD)
Characteristic | Oxford cohort | p-Value | Southampton cohort | p-Value | ||||
|---|---|---|---|---|---|---|---|---|
Control (n = 16) | Severe asthma | Control (n = 22) | asthma | |||||
Non-eosinophilc (n = 14) | Eosinophilic (n = 26) | Non-eosinophilc (n = 42) | Eosinophilic (n = 10) | |||||
Age (y) | 36.6 ± 12.6 | 62.3 ± 9.1 | 53.7 ± 13.7 | 0.0001 | 31.7 ± 11.9 | 38.4 ± 15.1 | 43.8 ± 15.4 | 0.1 |
Sex (male%) | 15 | 67 | 50 | 64 | 38 | 80 | 0.03 | |
Atopy (%) | 23 | 33 | 58 | 0 | 81 | 100 | <0.0001 | |
BMI | 22 ± 2.7 | 27.7 ± 3.0 | 31.9 ± 7.2 | 0.0001 | 25.5 ± 4.9 | 29.2 ± 7.8 | 28.12 ± 5.2 | 0.1 |
FEV1 (% pred) | 104.2 ± 10.5 | 76.8 ± 23.3 | 75.7 ± 23.9 | 0.0007 | 107.4 ± 13.8 | 88.6 ± 22.0 | 69.6 ± 22.3 | <0.0001 |
Sputum eosinophils (%) | 0.25 ± 0.12 | 1.4 ± 0.8 | 28.7 ± 24.0 | <0.0001 | 0.25 ± 0.65 | 0.72 ± 0.67 | 10.4 ± 10.2 | <0.0001 |
FeNO (ppb) | 26 ± 12 | 23 ± 9.0 | 38 ± 37 | 0.6 | 17 ± 7.1 | 42 ± 45 | 63 ± 48 | 0.001 |
Blood eosinophils (109/l) | 0.14 ± 0.08 | 0.24 ± 0.27 | 0.57 ± 0.3 | <0.0001 | 0.15 ± 0.07 | 0.21 ± 0.15 | 0.37 ± 0.28 | <0.05 |
Serum IgE (IU/ml) | 33 ± 53 | 271 ± 367 | 487 ± 820 | 0.001 | 37 ± 30 | 251 ± 401 | 541 ± 698 | 0.0002 |
ICS dose (BDP equivalent µg) | 0 | 1329 ± 574 | 1758 ± 486 | <0.0001 | 0 | 762 ± 794 | 1452 ± 1172 | <0.0001 |
Leukotriene receptor antagonist use, n (%) | 0 (0) | 4 (29) | 10 (38) | 0 (0) | 11 (26) | 4 (40) | ||
